JG
ABCL icon

Jefferies Group’s AbCellera Biologics ABCL Stock Holding History

Jefferies Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$376K Sell
38,000
-159,161
-81% -$1.75M ﹤0.01% 1140
2022
Q2 		$2.1M Buy
+197,161
New +$1.67M 0.02% 601

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Jefferies Group's ABCL Position: Q3 2022 in Review

Jefferies Group reduced its AbCellera Biologics (ABCL) stake by 81% in Q3 2022, selling an estimated $1.75M and leaving 38,000 shares worth $376K. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

Jefferies Group first reported a position in ABCL in Q2 2022 and has held it in 2 quarters since. The position peaked at $2.1M in Q2 2022. 190 funds tracked by Wall St. Rank hold ABCL as of Q3 2022.

  • Jefferies Group held 38,000 shares of AbCellera Biologics worth $376K as of Q3 2022.
  • Jefferies Group sold 159,161 AbCellera Biologics shares in Q3 2022, an estimated $1.75M.
  • AbCellera Biologics made up ﹤0.01% of Jefferies Group's portfolio in Q3 2022, its #1140 holding.
  • Jefferies Group first reported a position in AbCellera Biologics in Q2 2022 and has held it in 2 quarters since.
  • Jefferies Group's AbCellera Biologics position peaked at $2.1M in Q2 2022.
  • 190 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.